A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events
Moretti ME, Lato DF, Ungar WJ, Berger H, Koren G, Ito S
Record ID 32011000113
English
Authors' objectives:
The objective of the study was to determine the incremental costs of genotyping to avert neonatal adverse events during maternal pharmacotherapy.
Authors' recommendations:
Although genotyping to guide pharmacotherapy was not cost saving, the cost to avert an infant adverse event may represent good value for money. It is not yet known whether implementation would be clinically viable, however these findings will have implications for new mothers and their health care providers world-wide.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
https://lab.research.sickkids.ca/task/wp-content/uploads/sites/66/2018/06/2015-01-CYP2D6-TASK-Jun-11-FULL-REPORT.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cost-Benefit Analysis
- Infant, Newborn
- Pain
- Postpartum Period
- Pregnancy
- Pregnancy Complications
Contact
Organisation Name:
Technology Assessment at SickKids
Contact Address:
Program of Child Health Evaluative Sciences, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8 tel: (416) 813-8519 fax: (416) 813-5979
Contact Name:
wendy.ungar@sickkids.ca
Contact Email:
wendy.ungar@sickkids.ca
Copyright:
<p>The Hospital for Sick Children Research Institute</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.